Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Saved in:
| Title: | Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. |
|---|---|
| Authors: | Reid P; Division of Rheumatology, Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA., Sandigursky S; Division of Rheumatology, Department of Medicine, NYU Langone Health, New York, NY, USA., Song J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lopez-Olivo MA; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Safa H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cytryn S; Division of Internal Medicine, Department of Medicine, NYU Langone Health, New York, TX, USA., Efuni E; Division of Internal Medicine, Department of Medicine, NYU Langone Health, New York, TX, USA., Buni M; Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pavlick A; Medical Oncology, Weill Cornell Medical Center, New York, NY, USA., Krogsgaard M; Perlmutter Cancer Center, Department of Pathology, NYU Langone Health, New York, NY, USA., Abu-Shawer O; Department of Internal Medicine, Harvard Medical School, Boston, MA, USA.; Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA., Altan M; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weber JS; Perlmutter Cancer Center, Department of Medicine, NYU Langone Health, New York, NY, USA., Rahma OE; Department of Internal Medicine, Harvard Medical School, Boston, MA, USA.; Department of Oncology, Dana Farber Cancer Institute, Boston, MA, USA.; Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA., Suarez-Almazor ME; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abdel-Wahab N; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt. |
| Source: | Oncoimmunology [Oncoimmunology] 2023 Oct 30; Vol. 12 (1), pp. 2261264. Date of Electronic Publication: 2023 Oct 30 (Print Publication: 2023). |
| Publication Type: | Observational Study; Multicenter Study; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2162-402X |
|---|---|
| DOI: | 10.1080/2162402X.2023.2261264 |
